Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue is expected to grow to Rs. 1,600-1,800 crores by FY 2027-28, recovering from the current lower base. Operating profit margins (EBITDA) are targeted at 16%-17% minimum in the next two years, potentially reaching 20% in longer term. The worst financial performance is considered behind; growth and profitability improvements expected starting June 2026. New patented products launched recently are anticipated to drive revenue and profitability growth in the coming years. Current capacity can support Rs. 2,000+ crore revenue without additional CAPEX, indicating scalability. Cost ra

Any current/future new fundraising through debt or equity?

The company has received 25% of the preferential issue amount, which has been utilized for working capital. The remaining 75% of the preferential amount, planned primarily for CAPEX (new plant), has not yet been received. Currently, there are no active plans for fund-raising through promoters or institutions for CAPEX, as the company has sufficient capacity for the next two years. The company is monitoring the market situation before deciding on actions regarding the balance 75% installment or alternative funding. If the pending preferential funds are not received, the company may consider ext

Any current/future capex/capital investment/strategic investment?

Currently, there is no active CAPEX being undertaken ("So, for CAPEX, we are not doing anything as of now" - Vikas Jain, Page 17). The CAPEX plan depends on receiving the balance 75% amount from preferential allotment. Only the initial 25% amount received was used for working capital (Page 17). The company plans to reassess the CAPEX decision "four, five months down the line" and is currently keeping CAPEX on hold (Page 16). Existing capacity is sufficient to achieve revenues beyond Rs. 1,800 crore without adding new capacity (Page 9). Any future strategic investments, such as international ex

Future growth expectations in sales/revenue/volumes?

Company expects growth to resume from next year after stabilizing inventory and working capital. Projected revenue for FY 2026 is Rs. 1,300 to Rs. 1,400 crore, with sales growth anticipated in FY 2027 to Rs. 1,600 - 1,800 crore. Over next two years, revenue expected to exceed past peak levels, driven by patented products. Operating profit margin (OPM) target for FY 2027 is around 16-17%, with a long-term goal up to 20%. Existing production capacity sufficient to support Rs. 2,000+ crore revenue without additional CAPEX. Growth fueled by expanding patented portfolio and new product launches, wi

IN US

Sale is live|00:00:00left today

Best Agrolife LtdQ4 FY27Fertilizers & Agrochemicals

Best Agrolife Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹15.5P/E: 28.8Market Cap: ₹697 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Order

N/A

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Company expects growth to resume from next year after stabilizing inventory and working capital.
→Projected revenue for FY 2026 is Rs. 1,300 to Rs. 1,400 crore, with sales growth anticipated in FY 2027 to Rs. 1,600 - 1,800 crore.
→Over next two years, revenue expected to exceed past peak levels, driven by patented products.
→Operating profit margin (OPM) target for FY 2027 is around 16-17%, with a long-term goal up to 20%.
→Existing production capacity sufficient to support Rs. 2,000+ crore revenue without additional CAPEX.
→Growth fueled by expanding patented portfolio and new product launches, with improved sales team and policies.
→Export business and international expansion seen as a significant growth driver over time.
→Management confident worst sales and EBITDA margin decline are behind, expecting upward trajectory going forward.

Margin guidance

Category 1

→Revenue is expected to grow to Rs. 1,600-1,800 crores by FY 2027-28, recovering from the current lower base.
→Operating profit margins (EBITDA) are targeted at 16%-17% minimum in the next two years, potentially reaching 20% in longer term.
→The worst financial performance is considered behind; growth and profitability improvements expected starting June 2026.
→New patented products launched recently are anticipated to drive revenue and profitability growth in the coming years.
→Current capacity can support Rs. 2,000+ crore revenue without additional CAPEX, indicating scalability.
→Cost rationalization on inventory, OPEX, and sales returns has improved EBITDA despite revenue pressures.
→Earnings per share (EPS) likely to improve in line with revenue and EBITDA growth but was under pressure due to recent challenges.
→Management is confident of returning to strong growth and profitability trajectory by FY 2027.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has received 25% of the preferential issue amount, which has been utilized for working capital.
→The remaining 75% of the preferential amount, planned primarily for CAPEX (new plant), has not yet been received.
→Currently, there are no active plans for fund-raising through promoters or institutions for CAPEX, as the company has sufficient capacity for the next two years.
→The company is monitoring the market situation before deciding on actions regarding the balance 75% installment or alternative funding.
→If the pending preferential funds are not received, the company may consider external funding in the future, but no commitment or immediate plan exists as of now.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Best Agrolife Limited. However, insights related to sales and order environment include: - The company faced lower sales in the current year due to unseasonal rainfall and market conditions but expects recovery starting June next year. - Inventory and sales return issues have been stabilized with stringent policies, aiding better dealer and sales team comfort. - New patented products such as BestMan and Fetagen have shown strong acceptance with over 4 lakh treated acres. - The company expects growth driven by these patented products and improved operational stability. - Export shipments continue on a cash basis with ongoing dossiers in international markets. - Capacity is adequate to handle revenues exceeding Rs. 2,000 crore without expansion. - Overall, growth in order flow is anticipated from FY 2027 onwards with better market conditions and product portfolio strength. No specific numeric order book or pending order values were disclosed.

Capex plans

→Currently, there is no active CAPEX being undertaken ("So, for CAPEX, we are not doing anything as of now" - Vikas Jain, Page 17).
→The CAPEX plan depends on receiving the balance 75% amount from preferential allotment. Only the initial 25% amount received was used for working capital (Page 17).
→The company plans to reassess the CAPEX decision "four, five months down the line" and is currently keeping CAPEX on hold (Page 16).
→Existing capacity is sufficient to achieve revenues beyond Rs. 1,800 crore without adding new capacity (Page 9).
→Any future strategic investments, such as international expansion and new product registrations, are underway but not quantified as specific capital investments yet (Page 9).
→Focus remains on stabilizing operations, inventory, and working capital before considering fresh investments (Page 17).

How does Best Agrolife Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Best Agrolife Ltd

Rev 3Mar 1

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Best Agrolife Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio